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DMBA = 7,12-dimethylbenz(a) anthracene; ER = estrogen receptor; ESA = epithelial-specific antigen; PR = progesterone receptor; SP = side
population; TEB = terminal end bud.
Available online http://breast-cancer-research.com/contents/7/3/131
Abstract
Epidemiological, clinical, and experimental data indicate that the
risk of developing breast cancer is strongly dependent on the ovary
and on endocrine conditions modulated by ovarian function, such
as early menarche, late menopause, and parity. Women who gave
birth to a child when they were younger than 24 years of age
exhibit a decrease in their lifetime risk of developing breast cancer,
and additional pregnancies increase the protection. The breast
tissue of normally cycling women contains three identifiable types
of lobules, the undifferentiated Lobules type 1 (Lob 1) and the
more developed Lobules type 2 and Lobules type 3. The breast
attains its maximum development during pregnancy and lactation
(Lobules type 4). After menopause the breast regresses in both
nulliparous and parous women containing only Lob 1. Despite the
similarity in the lobular composition of the breast at menopause,
the fact that nulliparous women are at higher risk of developing
breast cancer than parous women indicates that Lob 1 in these
two groups of women might be biologically different, or might
exhibit different susceptibility to carcinogenesis. Based on these
observations it was postulated that Lob 1 found in the breast of
nulliparous women and of parous women with breast cancer never
went through the process of differentiation, retaining a high
concentration of epithelial cells that are targets for carcinogens
and are therefore susceptible to undergo neoplastic trans-
formation. These epithelial cells are called Stem cells 1, whereas
Lob 1 structures found in the breast of early parous post-
menopausal women free of mammary pathology, on the contrary,
are composed of an epithelial cell population that is refractory to
transformation, called Stem cells 2. It was further postulated that
the degree of differentiation acquired through early pregnancy has
changed the ‘genomic signature’ that differentiates Lob 1 of the
early parous women from that of the nulliparous women by shifting
the Stem cells 1 to Stem cells 2 that are refractory to carcino-
genesis, making this the postulated mechanism of protection
conferred by early full-term pregnancy. The identification of a
putative breast stem cell (Stem cells 1) has, in the past decade,
reached a significant impulse, and several markers also reported
for other tissues have been found in the mammary epithelial cells of
both rodents and humans. Although further work needs to be
carried out in order to better understand the role of the Stem cells 2
and their interaction with the genes that confer them a specific
signature, collectively the data presently available provide evidence
that pregnancy, through the process of cell differentiation, shifts
Stem cells 1 to Stem cells 2 — cells that exhibit a specific genomic
signature that could be responsible for the refractoriness of the
mammary gland to carcinogenesis.
The protective effect of parity in breast cancer
The incidence of breast cancer has gradually increased in the
United States and in most Western countries over the past
few decades [1]. Although the reasons for this increase are
not certain, epidemiological, clinical, and experimental data
indicate that the risk of developing breast cancer is strongly
dependent on the ovary and on endocrine conditions
modulated by ovarian function, such as early menarche, late
menopause, and parity [1-3].
Women who gave birth to a child when they were younger
than 24 years of age exhibit a decrease in their lifetime risk of
developing breast cancer, and additional pregnancies
increase the protection [3]. The protective effect of full-term
pregnancy is a well-established concept not only in humans,
but also in experimental rodent models [4-12]. A plausible
explanation for the lifetime protective effect of an event
occurring so early in life is provided by the biological behavior
of breast cancer and by comparative studies with
experimental animal models [9,10,13].
In rodents, maximal incidence of 7,12-dimethylbenz(a)
anthracene (DMBA)-induced mammary cancer occurs when
the carcinogen is administered to young virgin cycling rats,
but the same carcinogen fails to induce tumors when given to
rats after a full-term pregnancy [4-13]. The high susceptibility
of the young virgin rat mammary gland to develop
malignancies is the result of the interaction of the carcinogen
with the rapidly dividing epithelium composing the terminal
end buds (TEBs), which are undifferentiated ductal structures
of the mammary parenchyma. Both the binding of the
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carcinogen DMBA to the DNA of rapidly proliferating
epithelial cells and a low DNA repair capacity result in fixation
of transformation, leading to the initiation of cancer [13-17].
There are close similarities between the pathogenesis of
breast cancer in women and that induced in rodents by
chemical carcinogens. Ductal carcinoma, the most frequently
diagnosed breast malignancy, originates in Lobules type 1
(Lob 1), also called the terminal ductal lobular unit, an
undifferentiated structure considered to be equivalent to the
TEB, the site of origin of ductal carcinomas in rodents
[18,19]. Importantly, under in vitro conditions, epithelial cells
from Lob 1 can be transformed by the same chemical
carcinogens that induce mammary cancer in experimental
animals [20,21].
These observations suggest that if the human breast is
exposed to a carcinogenic insult early in life, then Lob 1
would be the structure affected. It is therefore possible to
postulate that genomic damage caused by radiation,
environmental carcinogens, hormonal imbalances, and/or
other still unidentified factors, either alone or in combination
with genetic predisposition, might cause breast cancer in
women. For cancer to develop, however, this multifactorial
combination must occur during the window of high
susceptibility that is encompassed between menarche and
the first full-term pregnancy, even though the damaged cells
would be clinically detectable as a neoplasm only after
several years of progressing along the various stages of
transformation [5]. An initial mutagenic event taking place in
the primitive ductal structures of the breast before or during
puberty could therefore multiply during the process of
branching and ductal elongation driven by puberty and sexual
maturation (Fig. 1).
Breast development and differentiation
during pregnancy
The breast tissue of normally cycling women contains three
identifiable types of lobules: the previously described Lob 1,
and the more developed Lobules type 2 (Lob 2) and Lobules
type 3 (Lob 3) [21-23]. The lobular composition of the breast
of sexually mature women is influenced by numerous
endogenous and exogenous factors. Principal among them are
age, and hence the number and regularity of menstrual cycles,
endocrine imbalances, the use of exogenous hormones,
environmental exposures that could act as endocrine
disruptors, and the physiological condition of pregnancy.
The breast attains its maximum development during
pregnancy. This development occurs in two distinctly
dominant phases. The early stage, characterized by ductal
lengthening and profuse branching, is sustained by active cell
proliferation at the distal end of the ductal tree. The rapid
increase in the number of newly formed ductules results in
the progression of Lob 2 to Lob 3. This growth phase is
followed by the functional or secretory phase, which is
indicative of the progression from ductules to secretory acini
that characterize the fully differentiated Lobules type 4
(Lob 4). After post-lactational involution Lob 4 regress to
Lob 3, which remain present as the predominant structure in
the breast until a woman reaches the fourth decade of life,
decreasing thereafter due to their involution to Lob 2 and
Lob 1 [21,22].
In contrast to the breast of parous women, the nulliparous
breast contains a great number of Lob 1, whose percentage
remains almost constant throughout their lifespan. Lob 2 are
present in moderate numbers and Lob 3 are almost totally
absent during the early reproductive years, whereas the
number of Lob 1 remains significantly higher. This obser-
vation suggests that a certain percentage of Lob 1 might
have progressed to Lob 2, but very few of them had
progressed to Lob 3 [22].
The breast regresses in both nulliparous and parous women
after menopause. This phenomenon is manifested as an
increase in the number of Lob 1, and a concomitant decline in
the number of Lob 2 and Lob 3. At the end of the fifth decade
of life, the breast of both nulliparous and parous women
contains predominantly Lob 1 [22]. Despite the similarity in
the lobular composition of the breast, the fact that nulliparous
women are at higher risk of developing breast cancer than
parous women indicates that Lob 1 in these two groups of
women might be biologically different, or might exhibit
different susceptibility to carcinogenesis [22,23].
Pregnancy and the pathogenesis of breast
cancer
An important concept that emerged from the study of breast
development is that Lob 1, which corresponds to a specific
stage of development of the mammary parenchyma, has been
Figure 1
An initial mutagenic event in the primitive ductal structures of the
breast taking place early in life, such as before or during puberty, can
multiply during the process of branching and ductal elongation during
puberty and sexual maturation, explaining the development of a
neoplastic lesion later on in life.133
identified as the site of origin of the most common breast
malignancy, the ductal carcinoma. This site is demonstrated
in comparative studies of normal breasts and cancer-bearing
breasts obtained at autopsy and from cancer-bearing
lumpectomy or mastectomy specimens [18,19,23]. The
findings that the non-tumoral parenchyma in cancer-
associated breasts contained a significantly higher number of
hyperplastic terminal ducts, atypical Lob 1, and ductal
carcinomas in situ originated in Lob 1 than those breasts of
women free of breast cancer indicate that Lob 1 develop
preneoplastic lesions as well as neoplastic lesions [18].
More differentiated lobular structures have been found to
originate tumors whose malignancy is inversely related to the
degree of differentiation of the parent structure; that is, Lob 2
originate lobular carcinomas in situ; Lob 3 give rise to benign
breast lesions, such as hyperplastic lobules, cysts, fibro-
adenomas, and adenomas; and Lob 4 originate lactating
adenomas [18]. The fact that each specific compartment of
the breast gives origin to a specific type of lesion lends
support to a new biological concept; that the differentiation of
the breast determines its susceptibility to neoplastic trans-
formation [18,24].
The architecture of the non-tumoral breast tissues from nulli-
parous women’s cancer-bearing lumpectomy or mastectomy
specimens does not differ from that of nulliparous females
free of mammary pathology, both being composed pre-
dominantly of Lob 1 [23,25]. Although in premenopausal
parous women from the general population the breast
contains predominantly Lob 3 and a very low percentage of
Lob 1, in those parous women with or without family history
that had developed breast cancer the breast tissues contain
Lob 1 as the predominant structure, appearing similar to that
of nulliparous women [25]. The similarities found between the
architecture of the breast of nulliparous women and that of
parous women with cancer support the hypothesis that the
degree of breast development is of importance in the
susceptibility to carcinogenesis, and, furthermore, that parous
women who develop breast cancer might exhibit a defective
response to the differentiating influence of the hormones of
pregnancy [22] and therefore be hosting cells that are
susceptible to carcinogenesis.
Based on these observations it was postulated by Russo and
Russo in 1997 that Lob 1 found in the breast of nulliparous
women and of parous women with breast cancer never went
through the process of differentiation, retaining a high
concentration of epithelial cells that are targets for
carcinogens and are therefore susceptible to undergo
neoplastic transformation — these cells were called Stem
cells 1 (Fig. 2) [26]. Lob 1 structures found in the breast of
early parous postmenopausal women free of mammary
pathology, on the other hand, are composed of an epithelial
cell population that is refractory to transformation — these
cells were called Stem cells 2 (Fig. 2) — making this the
postulated mechanism of protection conferred by early full-
term pregnancy [22-24,26]. It was further postulated that the
degree of differentiation acquired through early pregnancy
has changed the ‘genomic signature’ that differentiates Lob 1
of the early parous women from those of the nulliparous
women by shifting the Stem cells 1 to Stem cells 2 that are
refractory to carcinogenesis (Fig. 2).
Role of the progenitor/stem cells in
mammary gland development and their
relationship to the cells of origin of cancer
(Stem cells 1)
Morphological evidence for a stem cell in the mammary
gland
Stem cells in adult structures have been defined by their
ability for self-renewal and for generating a differentiated
progeny. In the mammary gland, DeOme and colleagues
demonstrated that fragments of different parenchymal
portions were able to generate fully functional mammary
outgrowths in mice, forming ductal and lobuloalveolar
structures composed of epithelial cells and myoepithelial
cells [27]. This concept was further developed by Kordon
and Smith [28], who demonstrated that the progeny from a
single cell may comprise the epithelial population of a fully
developed lactating mammary outgrowth in mice. The
development of the complete mammary tree from a small
portion of a duct or from single cells therefore attests to their
multifaceted potential.
It was not known, however, whether these progenitor/stem
cells would be capable of initiating cancer when exposed to a
carcinogenic agent. This issue was addressed by Russo and
colleagues [29-31], who demonstrated that cancer started in
TEBs present in the mammary gland of young virgin rats. The
analysis of these structures by electron microscopy allowed
one to characterize their cellular composition based upon cell
and nuclear size, the nuclear–cytoplasmic ratio, the amount of
chromatin condensation, the electron density of the
cytoplasm, the number and distribution of organelles, and the
presence or absence of Mg2+-dependent and Na+K+-
dependent ATPases. Based upon these criteria, in addition to
myoepithelial cells, three types of epithelial cells were
identified: light cells, intermediate cells, and dark cells
[30,31]. Dark cells were found to be the predominant type in
TEBs, intermediate cells and myoepithelial cells were present
in significantly lower percentages, and light cells were only
occasionally seen so their percentage was combined with
that of intermediate cells. The analysis of the DNA labeling
index revealed that all the cell types proliferated, although at
different rates, depending upon the type of cells and their
type of location within the mammary gland tree. Cell
proliferation was maximal in intermediate cells located in
TEBs, being significantly lower in dark cells and myoepithelial
cells found in the same location. High cell proliferation was
associated with greater incorporation of H3-DMBA and with a
progressive dominance of intermediate cells in DMBA-
Available online http://breast-cancer-research.com/contents/7/3/131134
induced intraductal proliferations and in ductal carcinomas
[5,31]. These results indicated that intermediate cells were
not only the targets of the carcinogen, but also the stem cells
of mammary carcinomas.
Further work by Bennett and colleagues demonstrated that
intermediate cells isolated from DMBA-induced mammary
tumors originated two cell types in culture [32]: the dark cell,
representing a terminally differentiated cell or a class in
transition to differentiation; and intermediate cells, which
could represent an undifferentiated or stem cell, a progenitor
of dark cells and myoepithelial cells. Rudland and colleagues
[33] isolated and characterized from the normal rat mammary
gland and from DMBA-induced mammary adenocarcinomas
epithelial cells that were cuboidal and gave rise to a mixture
of cuboidal and spindle-shaped cells resembling fibroblasts.
In confluent cultures, cuboidal cells acquired the morphology
of a third type of cells, which were dark, polygonal and with
many small vacuoles, resembling the dark cells
ultrastructurally described by Russo and colleagues [31].
Chepko and Smith [34] differentiated two division-competent
cell populations in the murine mammary epithelium: a subset
of ‘large light cells’ structurally and functionally compatible
with early stages of secretory differentiation; and ‘small light
cells’ that were the least differentiated, suggesting that the
large light cells were a direct precursor to terminally
differentiated cells, both secretory and myoepithelial.
Cell markers identifying the stem cells in the mammary
gland
A shift from the pioneering work performed for characterizing,
by morphology and by in vitro behavior, the progenitor/stem
cells started with the search for immunocytochemical and
genomic markers. Smith and colleagues [35] utilized the
expression of keratin 6 and keratin 14 in mouse mammary
epithelium for defining subsets of morphologically distinct
luminal mammary epithelial cells with kinetic properties
expected for latent mammogenic stem cells. Keratin 6 was
confined to a small number of mammary epithelial cells found
in the growing end buds and among the luminal epithelium,
whereas keratin 14 was expressed in basally located fusiform
cells as the myoepithelial cells. These authors emphasized
the usefulness of these markers for identifying mammary
epithelium-specific primordial cells.
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Figure 2
Breast cancer originates in undifferentiated terminal structures of the mammary gland (Lobules type 1) that contain Stem cells 1, the target of the
neoplastic event. Early parity induces differentiation of the mammary gland, creating Stem cells 2. Even though differentiation significantly reduces
cell proliferation in the mammary gland, the mammary epithelium remains capable of responding with proliferation to given stimuli, such as a new
pregnancy. Under these circumstances, however, the cells that are stimulated to proliferate are from structures that have already been primed by
the first cycle of differentiation, that are able to metabolize the carcinogen and repair the induced DNA damage more efficiently than the cells of the
nulliparous gland, and that are less susceptible to carcinogenesis. However, if the shifting of Stem cells 1 to Stem cells 2 has not been completed,
a powerful enough carcinogenic stimulus may overburden the system, thereby initiating successfully a neoplastic process.135
Stingl and colleagues [36,37] utilized new molecular markers
(Table 1) for selecting subpopulations of cells with distinct
differentiation potential. They described bipotent human
mammary epithelial progenitor cells based on the expression
of epithelial-specific antigen (ESA), sialomucin 1 (MUC1),
common acute lymphoblast antigen (CALLA/CD10), and α-
integrin, in combination with exclusion of rhodamine dye.
Hebbard and colleagues [38] observed that CD44, a member
of the family of cell surface proteins that is expressed in breast
carcinomas, is also expressed in the normal mammary gland.
CD44 expression in rodents is first detected at puberty, and
thereafter it is regulated by the estrous cycle; the expression
disappears during lactation and reappears during involution,
suggesting that the expression of this protein is a marker of a
stem cell. Novel studies in the mouse mammary gland have
identified stem cells in TEBs and ducts by pulse-labeling
primary mammary epithelial cells with fluorescent TRITC-cell
linker membrane label and with BrdU [39]. The cells were
then transplanted into cleared juvenile syngenic mammary fat
pads, in which they were identified as long-lived, label-
retaining mammary epithelial cells in mammary ducts that
were actively growing or static. That study demonstrated that
label-retaining mammary epithelial cells are stem cells and
that their progeny (transitional cells) are arranged as
transitional units, and also demonstrated that both cells
express Zonula Occludens-1 and α-catenin proteins, data
suggesting that transitional units retain stem cells.
The study of markers for other stem cells has been useful in
the identification of mammary stem/progenitor cells. Stem cell
antigen 1 (Sca1) (Table 1) was first described in mice as a
hematopoietic stem cell antigen [40]. Welm and colleagues
detected in the luminal epithelium of mice a Sca1+ cell
population that is enriched for functional stem/progenitor
cells [41]. These cells are BrdU label-retaining, lack
expression of differentiation markers, and are progesterone
receptor-negative. The Sca1+ population also shows ‘side
population’ (SP) properties, a characteristic first defined in
bone marrow cells [40], as cells with Hoechst dye-effluxing
properties that have phenotypic markers of multipotential
hematopoietic stem cells. It has been proposed that the
protein responsible for that phenotype is breast cancer
resistance protein (BCRP1), suggesting that the expression
of this protein could serve as a marker for stem cells from
various sources [42]. Mammary epithelial cells with SP
properties were also identified in the human mammary gland.
Alvi and colleagues [43] showed that 0.2–0.45% of both
human epithelia and mouse epithelia were formed by distinct
SP cells. These cells generated ductal and lobuloalveolar
structures when transplanted into murine cleared mammary
fat pads. The SP cells had a high expression of BCRP, Sca1,
and telomerase catalytic subunit, and had low levels of
differentiated markers for luminal cell types (epithelial
membrane antigen and cytokeratin 19) and myoepithelial cell
types (cytokeratin 14). These cells were detected in all
human breast samples studied, but their presence was not
correlated with age, parity, contraceptive use, or day of
menstrual cycle.
Further investigations identified new markers that may be
specific for the human stem/progenitor cells. Gudjonsson
and colleagues isolated a cell line derived from human
mammary cells expressing ESA and lacking MUC expression
that could give rise to both luminal epithelial cells and
myoepithelial cells in culture [44]. One single ESA+/MUC–
cell had the ability of generating a terminal ductal-lobular unit-
like structure in basement membrane gel, similar to that
formed when the cell line was implanted in mice. In contrast,
an ESA+/MUC+ subpopulation was differentiated and luminal
epithelial-restricted without stem cell properties (Table 1).
Wicha and colleagues developed a system to enrich the
population of human mammary progenitor/stem cells by
culturing them in suspension, where they formed ‘non-
adherent mammospheres’ [45]. These structures were able
to differentiate along all three mammary epithelial lineages
and to clonally generate complex functional structures in
three-dimensional culture systems. Cytological and immuno-
cytochemical analysis of secondary mammospheres revealed
that these structures contained cells positive for α6-integrin,
cytokeratin 5 (which was widely expressed), and CD10; ESA-
positive and cytokeratin 14-positive cells were less frequently
found. Muc1, α-smooth muscle antigen, and cytokeratin 18
were not detected. In addition to cells, mammospheres
contained extracellular material. However, immunostains for
fibronectin and collagen IV, the classical components of adult
gland extracellular material, were negative — although ~20%
of the mammospheres stained positive for laminin. In contrast,
abundant expression of the embryonic extracellular material
components tenascin and decorin, was detected in mammo-
spheres [45]. Moreover, the comparison of the genomic
profile of undifferentiated cells from mammospheres with that
of differentiated cells cultured on collagen identified gene
candidates for stem/progenitor cell markers. Some of these
genes were already described as involved in stem/progenitor
cell-specific functions or in regulation of self-renewal, and
abnormal expression of some of the genes has been
correlated with breast cancer development such as
proliferation, cell survival, and invasion (Table 1).
Role of steroid hormone receptors as markers of stem
cells in the mammary gland
The identification of the stem cell and of its role in the
development and differentiation of the mammary gland from
birth to senescence requires an understanding of the effect
of estrogen and its cognate ligand receptor alpha (ERα) in
these processes. The importance of the role played by the
ERα in mammary gland development has been highlighted by
the development of the αERKO mouse [46]. At birth, the
mammary gland of intact animals consists of a rudimentary
ductal tree that develops and fills the stroma of the gland in
response to increased ovarian estrogen at puberty. The
Available online http://breast-cancer-research.com/contents/7/3/131136
Breast Cancer Research    May 2005 Vol 7 No 3 Russo et al.
Table 1
Genes attributed to the stem cells of the mammary gland (Stem cells 1)
Gene Abbreviation Accession number Cytoband References
A disintegrin and metalloproteinase domain 12 (meltrin alpha) ADAM12 NP_067673 10q26.3 [45]
Actin alpha 1, alpha smooth muscle antigen ACTA1/ASMA NP_001091 1q42.13-q42.2 [45]
Apolipoprotein E APOE NP_000032 19q13.2 [45]
ATP-binding cassette, subfamily A, member 1 ABCA1 NP_005493 9q31.1 [45]
ATP-binding cassette, subfamily G, member 2 ABCG2/BCRP NP_004818 4q22 [42,43]
Catenin (cadherin-associated protein), alpha 1 (102 kDa) CTNNA1 NP_001894 5q31 [39]
CD44 antigen CD44 NP_001001392 11p13 [38]
Chemokine (C–C motif) ligand 2 CCL2 NP_002973 17q11.2-q21.1 [45]
Cyclin D2 CCND2 NP_001750 12p13 [45]
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A NP_510867 6p21.2 [49,50]
Decorin DCN NP_598014 12q13.2 [45]
Epithelial membrane protein 3 EMP3 NP_001416 19q13.3 [45]
Estrogen receptor 1 ESR1 NP_000116 6q25.1 [47,49-51]
Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2,  FGFR1 NP_075599 8p11.2-p11.1 [45]
Pfeiffer syndrome)
Flotillin 2 (epithelial-specific antigen) FLOT2/ESA NP_004466 17q11-q12 [36,37,44,51]
Four and a half LIM domains 1 FHL1 NP_001440 Xq26 [45]
Frizzled homolog 2 (Drosophila) FZD2 NP_001457 17q21.1 [45]
FYN oncogene related to SRC, FGR, YES FYN NP_694593 6q21 [45]
Glycoprotein (transmembrane) nmb GPNMB NP_002501 7p15 [45]
Glypican 4 GPC4 NP_001439 Xq26.1 [45]
Growth-associated protein 43 GAP43 NP_002036 3q13.1-q13.2 [45]
Growth hormone receptor GHR NP_000154 5p13-p12 [45]
Insulin-like growth factor 2 receptor IGF2R NP_000867 6q26 [45]
Insulin-like growth factor binding protein 4 IGFBP4 NP_001543 17q12-q21.1 [45]
Insulin-like growth factor binding protein 7 IGFPP7 NP_001544 4q12 [45]
Integrin, alpha 6 ITGA6 NP_000201 2q31.1 [36,37,45]
Keratin 19 KRT19 NP_002267 17q21.2 [48-50]
Lymphocyte antige 6 complex, sca-1 LY6A/SCA-1 NP_034868 15 [40,41,43]
Membrane metallo-endopeptidase (neutral endopeptidase,  MME/CALLA/CD10 NP_009220 3q25.1-q25.2 [36,37,45,
enkephalinase, CALLA, CD10) 49,51]
Mucin 1 (transmembrane), epithelial membrane antigen MUC1/EMA NP_877418 1q21 [36,37,43-45,
49,51]
Musashi homolog 1 (Drosophila) MSI1 NP_002433 12q24.1-q24.31 [49,50]
Nidogen (enactin) NID NP_002499 1q43 [45]
Notch homolog 1, translocation-associated (Drosophila) NOTCH1 NP_060087 9q34.3 [49]
Notch homolog 3 (Drosophila) NOTCH3 NP_000426 19p13.2-p13.1 [45]
Notch homolog 4 (Drosophila) NOTCH4 NP_004548 6p21.3 [49]
P53 target zinc finger protein WIG1 NP_689426 3q26.3-q27 [45]
Periostin, osteoblast specific factor POSTN NP_006466 13q13.3 [45]
Platelet-derived growth factor receptor, beta polypeptide PDGFRB NP_002600 5q31-q32 [45]
Polycystic kidney disease 2 (autosomal dominant) PKD2 NP_000288 4q21-q23 [45]
Progesterone receptor PGR NP_000917 11q22-q23 [41,47,49,50]
Prostate tumor overexpressed gene 1 PTOV1 NP_059128 19q13.33 [45]
Retinoic acid receptor responder (tazarotene induced) 3 RARRES3 NP_004576 11q23 [45]
Stem cell growth factor; lymphocyte secreted C-type lectin SCGF NP_002966 19q13.3 [45]
Telomerase reverse transcriptase TERT NP_937986 5p15.33 [43]
Tenascin C (hexabrachion) TNC NP_002151 9q33 [45]
Tight junction protein 1 (zona occludens 1) TJP1 NP_783297 15q13 [39]
Tissue inhibitor of metalloproteinase 3  TIMP3 NP_000353 22q12.1-q13.2 [45]
Wiskott–Aldrich syndrome protein interacting protein WASPIP NP_003378 2q31.1 [45]137
mammary gland of αERKO females does not grow beyond
the rudimentary ducts, illustrating the role of estrogens in
ductal elongation.
The importance of active ductal growth driven by estrogen
has been further emphasized by the higher susceptibility of
the breast to be transformed during a ‘high-risk’ window in
the lifespan of a female encompassed between menarche
and a first full-term pregnancy [5]. This period is
characterized by rapid ductal growth and active proliferative
activity of the mammary epithelium of Lob 1. These structures
are composed of a rapidly proliferating epithelium that has a
high content of ERα-positive and progesterone receptor
(PR)-positive cells. With the progressive maturation of Lob 1
to Lob 2, Lob 3, and Lob 4 there is a progressive decrease in
the percentage of proliferating cells, a reduction in the
percentage of cells positive for steroid hormone receptors,
and a reduction in the susceptibility of the cells to be
transformed by chemical carcinogens [47]. These data
indicate that the stem cells that originate the mammary tree
as well as cancerous lesions are located in a specific
compartment of the mammary parenchyma, namely Lob 1 or
the terminal ductal lobular unit; these are the cells that were
called Stem cells 1 by Russo and Russo [26].
Supporting studies by Petersen and colleagues [48] have
shown that a subset of suprabasal breast luminal epithelial
cells that are able to generate themselves, as well as
differentiated luminal epithelial cells and myoepithelial cells,
and are able to form terminal ductal lobular unit-like structures
are distinguished by expression of cytokeratin 19. The supra-
basal population of breast stem cells consists of undiffer-
entiated ‘intermediate’ cells with Hoechst dye-effluxing SP
properties. These cells lack expression of myoepithelial and
luminal apical membrane markers such as CALLA and
MUC1. The cells are rich for ERα-positive cells and express
several-fold higher levels of the ERα, p21 (CIP1), and Msi1
genes than non-SP cells (Table 1). These cells also form
branching structures in matrigel that included cells of both
luminal and myoepithelial lineages. These data suggest a
model where scattered steroid receptor-positive cells are
stem cells that self-renew through asymmetric cell division
and generate patches of transit-amplifying and differentiated
cells [49,50].
ERα/PR+ breast cancers exhibit loss of the two key
regulators of asymmetric cell division, Musashi-1 and
Notch-1, and thus they may arise from symmetric division of
the ERα/PR+ stem cell [49]. These data are supported by the
observations of Russo and colleagues that epithelial cells of
the Lob 1 co-express ERα, PR, and the proliferation marker
Ki67 [47], suggesting that these cells could originate ERα-
positive tumors. However, these cells represent less than 1%
of the total cell population whereas the majority of ERα/PR+
cells do not express the proliferation marker, an indication
that the cells that contain the receptors are not capable of
proliferating. The findings that proliferating cells are different
from those that are ERα-positive and PR-positive cells
support data that indicate estrogen controls cell proliferation
by an indirect mechanism.
Further support is the finding that when Lob 1 of normal
breast tissue are placed in culture, they lose the ERα-positive
cells, indicating that only proliferating cells that are also ERα-
negative can survive, representing a type of stem cell that
may originate ER-negative tumors [47]. The fact that the
majority of proliferating breast epithelial cells do not express
ERα and PgR could explain Clayton and colleagues’ [51]
data that cells characterized as human mammary stem cells
present ESA expression, Hoechst dye exclusion, low levels of
MUC-1 and CALLA, and lack detectable expression of ERα
and ERβ. Cells expressing that phenotype had high cloning
efficiency in culture from a single cell, generating mixed
colonies containing luminal cells and myoepithelial cells.
Further considerations and perspectives on the stem
cells of the mammary gland
As discussed in the previous sections, the identification of a
putative breast stem cell has in the past decade reached a
significant impulse, and several markers also reported for
other tissues have been found in the mammary epithelial cells
of both rodents and humans (Table 1). There are, however,
four main issues that require further investigation. The first is
to determine whether the stem cells or progenitor cells that
give origin to a complete mammary gland are the same cells
that are affected by a carcinogenic process. Another impor-
tant point that needs further clarification is the role of ERα as
a marker of the stem cells. The third issue is the need to be
extremely careful in validating conclusions drawn from in vitro
studies by properly confirming them with in vivo data, in
which numerous factors (such as age of the donor, repro-
ductive history, number of samples studied, and consider-
ation of intrinsic variability from sample to sample) are so
important, but seldom considered in the major publications
dealing with the stem cells in the mammary gland. Finally, the
data reported in the literature tend to support the concept
that the mammary gland contains Stem cells 1 that could be
the progenitor of the differentiated breast or could be the site
of origin of a neoplastic process. Supporting this concept is
the fact that all the genes ascribed to the stem cells in the
mammary gland are involved in more than one function of the
normal breast as well as the malignant breast.
The evidence for Stem Cells 2 found post pregnancy in
the mammary gland
Epidemiological studies in humans and experimental
carcinogenesis models have provided wide evidence of the
protective effect of pregnancy from breast cancer develop-
ment [2-12]. Russo and colleagues [5,10,17,52] have
postulated that the mechanism of pregnancy-induced
protection is mediated by the induction of mammary gland
differentiation driven by the hormonal milieu of pregnancy,
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which creates a specific genomic signature in the mammary
gland that makes this organ permanently refractory to
carcinogenesis. Alternative explanations attributed the
protective effect of pregnancy to changes in the environ-
mental milieu [53] and/or alterations in the immunological
profile of the host [7]. A further refinement of the hypothesis
of how pregnancy could be affecting cancer susceptibility
through induction of differentiation of the mammary gland
was first proposed by Russo and Russo [26], who postulated
that Lob 1 and the TEB found in the breast of nulliparous
women or of young virgin rats, respectively, had not
completed their differentiation into Lob 2, Lob 3, and Lob 4,
retaining a high concentration of stem cells (Stem cells 1),
which are susceptible to undergo neoplastic transformation
when exposed to a carcinogenic agent (see previous section
and Fig. 2) [26]. After the postmenopausal involution of the
mammary gland, the architecture of the parous breast is
similar to the nulliparous breast, containing predominantly
Lob 1 composed of Stem cells 2, an epithelial cell population
that is refractory to transformation (Fig. 2).
It was further postulated that the degree of differentiation
acquired through early pregnancy permanently changes the
‘genomic signature’ that differentiate Lob 1 of early parous
women from that of nulliparous women, shifting the Stem
cells 1 to Stem cells 2 that are refractory to carcinogenesis
(Fig. 2). These cells were called Stem cells 2 because, after
post-lactational involution, the mammary epithelium remains
capable of responding with proliferation and differentiation
to the stimulus of a new pregnancy; however, these cells are
refractory to carcinogenesis, even though they are
stimulated to proliferate and to regenerate the whole
mammary gland. Stem cells 2 are characterized by having a
genomic signature that has been induced by the first cycle of
differentiation (Fig. 2).
Supporting evidence to this hypothesis has been generated
during the past 8 years by Russo and colleagues as well as
by other researchers. Recent studies by Smith and colleagues
[54-56] using transgenic whey acidic protein-driven Cre and
Rosa 26-fl-stop-fl-LacZ mice provided evidence of a new
mammary epithelial cell population that originates from
differentiating cells during pregnancy; 5–10% of this parity-
induced epithelium survives post-lactational involution after
the first pregnancy. With successive pregnancies the
population percentage increases, reaching 60% of the total
epithelium in multiparous females. The parity-induced
mammary epithelial cells (PI-MEC) are equivalent to Stem
cells 2 as postulated by Russo and Russo [26] since these
cells show capacity for self-renewal and contribute to
mammary outgrowth in transplantation studies. PI-MEC can
function as alveolar progenitors in subsequent pregnancies,
and it is thought that they would be related to differences in
response to hormonal stimulation and carcinogenic agents
observed between nulliparous females and parous females
[54-56].
Several authors have focused on finding molecular changes
as a mechanism of pregnancy-induced protection [57-64]
(Table 2). Russo and colleagues have found that the post-
pregnancy involuted mammary gland exhibits a genomic
signature characterized by elevated expression of genes
involved in the apoptotic pathways, such as testosterone
repressed prostate message 2 (TRPM2), interleukin-1β-
converting enzyme, bcl-XL, bcl-XS, p53, p21, and c-myc,
which can be from threefold to fivefold upregulated
[57,58,65] (Table 2). The activation of programmed cell
death genes occurs through a p53-dependent process,
modulated by c-myc and with partial dependence on the
bcl2-family related genes. In addition, inhibin A and inhibin B,
heterodimeric non-steroidal secreted glycoproteins with tumor
suppressor activity, are also upregulated [57,58,65,66].
Genes whose level of expression progressively increases
with time of pregnancy, reaching their highest levels between
21 and 42 days post-partum, are those coding for a fragment
of glycogen phosphorylase, AMP-activated kinase, bone
morphogenetic protein 4, and vesicle-associated protein 1.
The G/T mismatch-specific thymine DNA glycosylase gene is
also increased fivefold in this model (Table 2).
These data indicate that the activation of genes involved in
the DNA repair process is part of the signature induced in the
mammary gland by pregnancy. These observations confirm
previous in vivo findings that the ability of the cells to repair
carcinogen-induced damage by unscheduled DNA synthesis
and adduct removal is more efficient in the parous and animal
mammary gland [17]. In concordance with the studies of
Srivastava and colleagues [57], Sivaraman and colleagues
[61] observed that p53 can be implicated in the protective
effect of parity, which can be mimicked by treatment of virgin
rats with estrogen and progesterone. Studies by Medina and
Kittrell [59,60] in the same hormonal model reported that the
function of p53 is required for the hormone-mediated
protection of DMBA-induced mammary tumorigenesis in mice
(Table 2).
Genomic analysis of the mammary gland of virgin rats treated
with estrogen and progesterone at doses that have been
reported to mimic pregnancy showed downregulation of
certain growth-promoting molecules, whereas markers
involved in cell cycle control or in the modulation of the
transforming growth factor beta signaling pathway were
upregulated in the post-treatment involuted mammary gland
[62]. In that study, an unknown non-coding RNA (designated
G.B7) and RbAp46, which has been implicated in a number
of complexes involving chromatin remodeling, were found to
be persistently upregulated in the lobules of the regressed
glands (Table 2). Using gene profile analysis, D’Cruz and
colleagues [64] also observed downregulation of growth
factors potentially involved in epithelial proliferation, as well as
persistent upregulation of transforming growth factor beta 3
and several of its transcripts targets in the involuted gland of
parous rats and mice (Table 2).
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Table 2
Genes found after pregnancy or pregnancy-like conditions in the mammary gland (Stem cells 2)
Gene Abbreviation Accession number Cytoband References
Adenosine deaminase ADA NP_000013 20q12-q13.11 [64]
Adipose differentiation-related protein ADFP M93275 [64]
B-cell CLL/lymphoma 2 BCL2 NP_000648 18q21.33 [57]
bcl-XL BCL-XL NP_612815 20q11.21 [57]
bcl-XS BCL-XS NP_001182 20q11.21 [57]
Bone morphogenetic protein 4 BMP4 NP_570912 14q22-q23 [57,58,66]
Carbonic anhydrase 2 CAR2 NP_000058 8q22 [64]
Carboxyl ester lipase CEL NP_001798 9q34.3 [64]
Casein alpha CSNA NP_001881 4q21.1 [62,64]
Casein beta CSNB NP_001882 4q21.1 [57,64]
Casein gamma CSNG D10215 [64]
Casein kappa CSNK NP_005203 4q21.1 [64]
Caspase 1, apoptosis-related cysteine protease (interleukin-1,  CASP1 NP_150637 11q23 [57]
beta, convertase)
Catechol-O-methyltransferase COMT NP_009294 22q11.21-q11.23 [57]
Cell division cycle 42 CDC42 NP_426359 1p36.1 [62]
Chitinase 3-like 1 CHI3L1 NP_001267 1q32.1 [64]
Clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2,  CLU NP_976084 8p21-p12 [57,64]
testosterone-repressed prostate message 2, apolipoprotein J)
c-myc proto-oncogene (myelocytomatosis viral oncogene homolog, avian) MYC NP_002458 8q24.12-24.13 [57]
Collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal  COL2A1 NP_149162 12q13.11-q13.2 [57]
dysplasia, congenital)
Collagen, type III, alpha 1 COL3A1 NP_000081 2q31 [57]
Cyclin D1 CCND1 NP_444284 11q13 [64]
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A NP_510867 6p21.2 [57]
Decorin DCN NP_598014 12q13.2 [62]
Extracellular proteinase inhibitor EXPI X93037 [64]
Fatty acid binding protein 3 (mammary-derived growth inhibitor) FABP3 NP_004093 1p33-p32 [57]
Folate-binding protein 1 ET63126 [64]
Follistatin-related protein FSTL1 NP_077345 2 [62]
G/T mismatch-specific thymine DNA glycosylase MTDG/TDG NP_003202 12q24.1 [57,58,66]
Glycogen phosphorylase NP_005600 11q12-q13.2 [57,58,66]
Heme-binding protein PRDX1 NP_476455 5q36 [62]
Heterogeneous nuclear ribonucleoprotein A1 HNRPA1 NP_112420 12q13.1 [62]
Immunoglobulin A heavy chain IgA J00475 [64]
Immunoglobulin G heavy chain IgG ET61798 [64]
Immunoglobulin M heavy chain IgM ET61785 [64]
Inhibin, alpha INHA NP_002182 2q33-q36 [58,66]
Inhibin, beta B (activin AB beta polypeptide) INHBB NP_002184 2cen-q13 [58,66]
Inhibitor of DNA binding 2 IDB2 NP_002157 2p25 [64]
Kappa-immunoglobulin light chain KIG LC X16678 [64]
Lactalbumin, alpha LALBA NP_002280 12q13 [57,64]
Lactotransferrin LTF NP_002334 [64]
Lipocalin 2 (oncogene 24p3) LCN2 NP_005555 9q34 [64]
Lipopolysaccharide binding protein LBP NP_004130 20q11.23-q12 [64]
Lysozyme P LYP NP_000230 12q15 [64]
Macrophage expressed gene 1 MPEG1 XP_166227 11q12.1 [64]
Matrix metalloproteinase 12 MMP12 NP_002417 11q22.3 [64]
Nap 1, Cdc42guanine exchange factor 9 ARHGEF9 NP_076447 Xq31 [62]
Phosphorylase, glycogen; muscle (McArdle syndrome,  PYGM NP_005600 11q12-q13.2 [57,58,66]
Glycogen storage disease type V)
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The proposed model of parity-induced specific changes [26]
has been further confirmed by Ginger and Rosen [63], who
reported that pregnancy induces multiple changes in the
mammary epithelial cells, including nuclear accumulation of
p53 and induction of whey acidic protein. During involution a
large component of the epithelium is eliminated through
apoptosis, and a specific subpopulation of epithelial cells
survives this process. The involuted mammary gland has
persistent changes in gene expression, nuclear localization of
p53, and an altered proliferative capacity in response to a
carcinogen. Pregnancy would induce epigenetic changes,
such as chromatin remodeling, DNA methylation/demethy-
lation, and histone modifications, affecting cell fate in the
parous mammary gland. As depicted in Table 2, all the genes
that have been attributed to Stem cells 2 seem to work in
different functional pathways than those described for Stem
cells 1 (Table 1).
Although further work needs to be carried out in order to
better understand the role of Stem cells 2 and their
interaction with the genes that confer their specific signature,
collectively the data described present evidence that
pregnancy, through the process of cell differentiation, shifts
Stem cells 1 to Stem cells 2 — cells that exhibit a specific
genomic signature that could be responsible for the
refractoriness of the mammary gland to carcinogenesis.
Unifying concepts
Breast cancer originates in undifferentiated terminal
structures of the mammary gland. The terminal ducts of Lob 1
of the human female breast, which are the sites of origin of
ductal carcinomas, are at their peak of cell replication during
early adulthood, a period during which the breast is more
susceptible to carcinogenesis. The susceptibility of Lob 1 to
undergo neoplastic transformation has been confirmed by in
vitro studies, which have shown that this structure has the
highest proliferative activity and the highest rate of
carcinogen binding to the DNA [5]. More importantly, when
treated with carcinogens in vitro, Lob 1 epithelial cells
express phenotypes indicative of cell transformation [20].
These studies indicate that in the human breast the target cell
of carcinogens is found in a specific compartment whose
characteristics are the determinant factors in the initiation
event (Fig. 2). These target cells will become the stem cells
(Stem cells 1; Fig. 2) of the neoplastic event, depending upon
the topographic location within the mammary gland tree, the
age at exposure to a known or putative genotoxic agent, and
the reproductive history of the host.
The higher incidence of breast cancer observed in nulliparous
women supports this concept, because it parallels the higher
cancer incidence elicited by carcinogens in rodents when
exposure occurs at a young age. In addition, it has been
shown that early parity is associated with a pronounced
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Table 2 (continued)
Genes found after pregnancy or pregnancy-like conditions in the mammary gland (Stem cells 2)
Gene Abbreviation Accession number Cytoband References
Pleckstrin homology-like domain, family A, member 1 PHLDA1 NP_031376 12q15 [64]
Podocalyxin AF109393.1 7 [62]
Protein kinase, AMP-activated, alpha 1 catalytic subunit PRDAA1/AMPK NP_996790 5p12 [57,58,66]
Protein kinase, AMP-activated, alpha 2 catalytic subunit PRKAA2 NP_006243 1p31 [57,58,66]
Protein phosphatase-1, delta PPP1CB NP_037197 6q13 [62]
Retinoblastoma binding protein 7 (RbAp46) RBBP7 NP_114004 Xq21 [62]
Retinol binding protein 1, cellular RBP1 NP_002890 3q23 [64]
Ring zinc finger protein RZFP AF037205.1 3 [62]
Secreted phosphoprotein 1 SPP1 NP_000573 4q21-q25 [64]
Sp3 transcription factor SP3 NP_003102 2q31 [62]
Stearyl-CoA desaturase (acyl-CoA desaturase, fatty acid desaturase,  SCOAD NP_005054 10q23-q24 [62]
delta(9)-desaturase)
Thymosin beta 4 TMSB4X NP_066932 Xq21.3-q22 [57]
Transferrin TNSF NP_058751 8q32 [62]
Transforming growth factor, beta 3 TGFB3 NP_003230 14q24 [64]
Tumor protein p53 (Li–Fraumeni syndrome) TP53 NP_000537 17p13.1 [57,59-61,63]
Tyrosine phosphatase Prl-1 PTP4A1 NP_113767 9q21 [62]
Vesicle-associated membrane protein 1 (synaptobrevin 1) VAMP1 NP_954740 12p [57,58,66]
Whey acidic protein WAP J00544 [64]
Zinc finger protein ZFP U90919 [62]
Zinc finger protein, Pzf PZF U05343.1 [62]141
decrease in the risk of breast cancer, and additional live
births confer greater risk reduction [3]. The protection
afforded by early full-term pregnancy in women could thus be
explained by the higher degree of differentiation of the
mammary gland at the time at which an etiologic agent, or
etiologic agents, act. Even though differentiation significantly
reduces cell proliferation in the mammary gland, the
mammary epithelium remains capable of responding with
proliferation to given stimuli, such as a new pregnancy
(Fig. 2). Under these circumstances, however, the cells that
are stimulated to proliferate are from structures that have
already been primed by the first cycle of differentiation,
becoming Stem cells 2 (Fig. 2) that are able to metabolize
carcinogen(s) and repair DNA damage more efficiently than
the cells of the virginal gland, thus becoming less susceptible
to carcinogenesis, as has been demonstrated in the rodent
experimental system. However, if the shift of Stem cells 1 to
Stem cells 2 has not been completed, a powerful enough
carcinogenic stimulus may overburden the system, thereby
initiating successfully a neoplastic process. Such conditions
may explain the small fraction of women developing breast
cancer after an early first full-term pregnancy (i.e. because
they have not had a full completion of the first cycle of
differentiation).
The findings that differentiation is a powerful inhibitor of
cancer initiation provide a strong rationale for pursuing the
identification of the stem cells susceptible to carcinogenesis
and of the genes that control this process. The knowledge
gained will provide novel tools for developing rational
strategies for breast cancer prevention.
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